159 related articles for article (PubMed ID: 21944123)
1. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.
Baden J; Adams S; Astacio T; Jones J; Markiewicz J; Painter J; Trust C; Wang Y; Green G
J Urol; 2011 Nov; 186(5):2101-6. PubMed ID: 21944123
[TBL] [Abstract][Full Text] [Related]
2. Multicenter evaluation of an investigational prostate cancer methylation assay.
Baden J; Green G; Painter J; Curtin K; Markiewicz J; Jones J; Astacio T; Canning S; Quijano J; Guinto W; Leibovich BC; Nelson JB; Vargo J; Wang Y; Wuxiong C
J Urol; 2009 Sep; 182(3):1186-93. PubMed ID: 19625061
[TBL] [Abstract][Full Text] [Related]
3. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
4. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
Rogers CG; Gonzalgo ML; Yan G; Bastian PJ; Chan DY; Nelson WG; Pavlovich CP
J Urol; 2006 Nov; 176(5):2280-4. PubMed ID: 17070312
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
Gonzalgo ML; Pavlovich CP; Lee SM; Nelson WG
Clin Cancer Res; 2003 Jul; 9(7):2673-7. PubMed ID: 12855646
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
7. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.
Woodson K; O'Reilly KJ; Hanson JC; Nelson D; Walk EL; Tangrea JA
J Urol; 2008 Feb; 179(2):508-11; discussion 511-2. PubMed ID: 18076912
[TBL] [Abstract][Full Text] [Related]
10. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
12. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
13. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
14. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
[TBL] [Abstract][Full Text] [Related]
16. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
17. Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis.
Yoon HY; Kim SK; Kim YW; Kang HW; Lee SC; Ryu KH; Shon HS; Kim WJ; Kim YJ
J Biomol Screen; 2012 Aug; 17(7):987-92. PubMed ID: 22511308
[TBL] [Abstract][Full Text] [Related]
18. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
Clark JP; Munson KW; Gu JW; Lamparska-Kupsik K; Chan KG; Yoshida JS; Kawachi MH; Crocitto LE; Wilson TG; Feng Z; Smith SS
Clin Chem; 2008 Dec; 54(12):2007-17. PubMed ID: 18948370
[TBL] [Abstract][Full Text] [Related]
19. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
Trock BJ; Brotzman MJ; Mangold LA; Bigley JW; Epstein JI; McLeod D; Klein EA; Jones JS; Wang S; McAskill T; Mehrotra J; Raghavan B; Partin AW
BJU Int; 2012 Jul; 110(1):56-62. PubMed ID: 22077694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
